Skin permeating nanogel for the cutaneous co-delivery of two anti-inflammatory drugs

Biomaterials

Volumn 33, Issue 5, 2012, Pages 1607-1617

  Shah, Punit P ^a   Desai, Pinaki R ^a   Patel, Apurva R ^a   Singh, Mandip S ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

Author keywords

Allergic contact dermatitis; Imiquimod; Psoriasis; Skin delivery; Skin permeating nanogel; Surface modified PLGA chitosan nanoparticles

Indexed keywords

ANTI-INFLAMMATORY DRUGS; CARBOPOL; CONTACT DERMATITIS; DRUG DELIVERY SYSTEM; DRUG RELEASE; GELLING AGENTS; IMIQUIMOD; IN-VITRO; INFLAMMATORY DISORDERS; KETOPROFEN; LACTIDES; METHYL CELLULOSE; NANOGELS; PSORIASIS; SKIN DELIVERY; SKIN LAYER; STABILITY STUDY; SURFACE-MODIFIED; TOPICAL DELIVERY; UNIFORM DISPERSIONS;

CHITOSAN; DERMATITIS; DISPERSIONS; DRUG DELIVERY; DRUG PRODUCTS; GELS; NANOPARTICLES; OLEIC ACID; PERMEATION;

NANOSTRUCTURED MATERIALS;

CARBOMER; CHITOSAN; GELLING AGENT; HYDROXYPROPYLMETHYLCELLULOSE; INTERLEUKIN 17; INTERLEUKIN 23; KETOPROFEN; NANOPARTICLE; OLEIC ACID; POLYGLACTIN; SPANTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DERMIS; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; EPIDERMIS; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; SKIN ALLERGY; SKIN PERMEABILITY; VISCOSITY;

ADMINISTRATION, CUTANEOUS; AMINOQUINOLINES; ANIMALS; ANTI-INFLAMMATORY AGENTS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; METHYLCELLULOSE; MICE; MICE, INBRED C57BL; NANOPARTICLES; PARTICLE SIZE; PERMEABILITY; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE; PSORIASIS; RHEOLOGY; SKIN; SURFACE PROPERTIES; VISCOSITY;

EID: 83355166267     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.11.011     Document Type: Article

References (48)

1. Wang Z.H., Wang Z.Y., Sun C.S., Wang C.Y., Jiang T.Y., Wang S.L. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain. Biomaterials 2010, 31:908-915.
2. Sultana Y., Maurya D.P., Iqbal Z., Aqil M. Nanotechnology in ocular delivery: current and future directions. Drugs Today (Barc) 2011, 47:441-455.
3. Patlolla R.R., Chougule M., Patel A.R., Jackson T., Tata P.N., Singh M. Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J Control Release 2010, 144:233-241.
4. Pan Y., Li Y.J., Zhao H.Y., Zheng J.M., Xu H., Wei G., et al. Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int J Pharm 2002, 249:139-147.
5. Slutter B., Bal S., Keijzer C., Mallants R., Hagenaars N., Que I., et al. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. Vaccine 2010, 28:6282-6291.
6. Lee P.W., Hsu S.H., Tsai J.S., Chen F.R., Huang P.J., Ke C.J., et al. Multifunctional core-shell polymeric nanoparticles for transdermal DNA delivery and epidermal langerhans cells tracking. Biomaterials 2010, 31:2425-2434.
7. Barry B.W. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci 2001, 14:101-114.
8. Jensen L.B., Petersson K., Nielsen H.M. In vitro penetration properties of solid lipid nanoparticles in intact and barrier-impaired skin. Eur J Pharm Biopharm 2011, 79:68-75.
9. Babu R.J., Kikwai L., Jaiani L.T., Kanikkannan N., Armstrong C.A., Ansel J.C., et al. Percutaneous absorption and anti-inflammatory effect of a substance P receptor antagonist: spantide II. Pharm Res 2004, 21:108-113.
10. Kikwai L., Babu R.J., Kanikkannan N., Singh M. Preformulation stability of spantide II, a promising topical anti-inflammatory agent for the treatment of psoriasis and contact dermatitis. J Pharm Pharmacol 2004, 56:19-25.
11. Shinkai N., Korenaga K., Okumura Y., Mizu H., Yamauchi H. Microdialysis assessment of percutaneous penetration of ketoprofen after transdermal administration to hairless rats and domestic pigs. Eur J Pharm Biopharm 2011, 78:415-421.
12. Rancan F., Papakostas D., Hadam S., Hackbarth S., Delair T., Primard C., et al. Investigation of polylactic acid (PLA) nanoparticles as drug delivery systems for local dermatotherapy. Pharm Res 2009, 26:2027-2036.
13. Lademann J., Richter H., Teichmann A., Otberg N., Blume-Peytavi U., Luengo J., et al. Nanoparticles-an efficient carrier for drug delivery into the hair follicles. Eur J Pharm Biopharm 2007, 66:159-164.
14. Alvarez-Roman R., Barre G., Guy R.H., Fessi H. Biodegradable polymer nanocapsules containing a sunscreen agent: preparation and photoprotection. Eur J Pharm Biopharm 2001, 52:191-195.
15. Colonna C., Conti B., Perugini P., Pavanetto F., Modena T., Dorati R., et al. Ex vivo evaluation of prolidase loaded chitosan nanoparticles for the enzyme replacement therapy. Eur J Pharm Biopharm 2008, 70:58-65.
16. Jain G.K., Pathan S.A., Akhter S., Ahmad N., Jain N., Talegaonkar S., et al. Mechanistic study of hydrolytic erosion and drug release behaviour of PLGA nanoparticles: influence of chitosan. Polym Degrad Stab 2010, 95:2360-2366.
17. Senyigit T., Sonvico F., Barbieri S., Ozer O., Santi P., Colombo P. Lecithin/chitosan nanoparticles of clobetasol-17-propionate capable of accumulation in pig skin. J Control Release 2010, 142:368-373.
18. Alvarez-Roman R., Naik A., Kalia Y.N., Guy R.H., Fessi H. Enhancement of topical delivery from biodegradable nanoparticles. Pharm Res 2004, 21:1818-1825.
19. Luengo J., Weiss B., Schneider M., Ehlers A., Stracke F., Konig K., et al. Influence of nanoencapsulation on human skin transport of flufenamic acid. Skin Pharmacol Physiol 2006, 19:190-197.
20. Rowat A.C., Kitson N., Thewalt J.L. Interactions of oleic acid and model stratum corneum membranes as seen by 2H NMR. Int J Pharm 2006, 307:225-231.
21. Tanojo H., Bos-van Geest A., Bouwstra J.A., Junginger H.E., Boodé H.E. In vitro human skin barrier perturbation by oleic acid: thermal analysis and freeze fracture electron microscopy studies. Thermochimica Acta 1997, 293:77-85.
22. Samah N.A., Williams N., Heard C.M. Nanogel particulates located within diffusion cell receptor phases following topical application demonstrates uptake into and migration across skin. Int J Pharm 2010, 401:72-78.
23. Batheja P., Sheihet L., Kohn J., Singer A.J., Michniak-Kohn B. Topical drug delivery by a polymeric nanosphere gel: formulation optimization and in vitro and in vivo skin distribution studies. J Control Release 2011, 149:159-167.
24. Yuan X., Shah B.A., Kotadia N.K., Li J., Gu H., Wu Z. The development and mechanism studies of cationic chitosan-modified biodegradable PLGA nanoparticles for efficient siRNA drug delivery. Pharm Res 2010, 27:1285-1295.
25. Patlolla R.R., Desai P.R., Belay K., Singh M.S. Translocation of cell penetrating peptide engrafted nanoparticles across skin layers. Biomaterials 2010, 31:5598-5607.
26. Kouchakzadeh H., Shojaosadati S., Maghsoudi A., Vasheghani Farahani E. Optimization of PEGylation conditions for BSA nanoparticles using response surface methodology. AAPSPharmSciTech 2010, 11:1206-1211.
27. Ghouchi Eskandar N., Simovic S., Prestidge C. Nanoparticle coated submicron emulsions: sustained in vitro release and improved dermal delivery of all-trans-retinol. Pharm Res 2009, 26:1764-1775.
28. van der Fits L., Mourits S., Voerman J.S., Kant M., Boon L., Laman J.D., et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 2009, 182:5836-5845.
29. Chatterjee A., Babu R., Klausner M., Singh M. In vitro and in vivo comparison of dermal irritancy of jet fuel exposure using EpiDerm (EPI-200) cultured human skin and hairless rats. Toxicol Lett 2005, 167:85-94.
30. Chougule M.B., Patel A., Jackson T., Singh M. Antitumor activity of noscapine in combination with doxorubicin in triple negative breast cancer. PLoS One 2011, 6:e17733.
31. Chougule M.B., Patel A.R., Sachdeva P., Jackson T., Singh M. Anticancer activity of noscapine, an opioid alkaloid in combination with cisplatin in human non-small cell lung cancer. Lung Cancer 2011, 71:271-282.
32. Lee C.H., Moturi V., Lee Y. Thixotropic property in pharmaceutical formulations. J Control Release 2009, 136:88-98.
33. Mortazavi S.A., Tabandeh H. The influence of various silicones on the rheological parameters of AZG containing silicone-based gels. Iran J Pharm Res 2005, 4:205-211.
34. Ramachandran S., Chen S., Etzler F. Rheological characterization of hydroxypropylcellulose gels. Drug Dev Ind Pharm 1999, 25:153-161.
35. Kikwai L., Babu R.J., Prado R., Kolot A., Armstrong C.A., Ansel J.C., et al. In vitro and in vivo evaluation of topical formulations of spantide II. AAPS Pharm Sci Tech 2005, 6:E565-E572.
36. Pena L.E., Lee B.L., Stearns J.F. Structural rheology of a model ointment. Pharm Res 1994, 11:875-881.
37. Baumgartner S., Kristl J., Peppas N.A. Network structure of cellulose ethers used in pharmaceutical applications during swelling and at equilibrium. Pharm Res 2002, 19:1084-1090.
38. Pople P., Singh K.K. Targeting tacrolimus to deeper layers of skin with improved safety for treatment of atopic dermatitis. Int J Pharm 2010, 398:165-178.
39. Puglia C., Blasi P., Rizza L., Schoubben A., Bonina F., Rossi C., et al. Lipid nanoparticles for prolonged topical delivery: an in vitro and in vivo investigation. Int J Pharm 2008, 357:295-304.
40. Choi S.P., Kim S.P., Kang M.Y., Nam S.H., Friedman M. Protective effects of black rice bran against chemically-induced inflammation of mouse skin. J Agric Food Chem 2010, 58:10007-10015.
41. Ansel J.C., Kaynard A.H., Armstrong C.A., Olerud J., Bunnett N., Payan D. Skin-nervous system interactions. J Invest Dermatol 1996, 106:198-204.
42. Cabrini D.A., Moresco H., Imazu P., da Silva C.D., Pietrovski E.F., Mendes D.A., et al. Analysis of the potential topical anti-inflammatory activity of averrhoa carambola L. in mice. Evid Based Complement Alternat Med 2011, Available from:. http://www.hindawi.com/journals/ecam/2011/908059/, 10.1093/ecam/neq026).
43. Tsuruta D. NF-kappa-B links keratinocytes and lymphocytes in the pathogenesis of psoriasis. Recent Pat Inflamm Allergy Drug Discov 2009, 3:40-48.
44. Guilloteau K., Paris I., Pedretti N., Boniface K., Juchaux F., Huguier V., et al. Skin inflammation induced by the synergistic action of IL-17A, IL-22, oncostatin M, IL-1{alpha}, and TNF-{alpha} recapitulates some features of psoriasis. J Immunol 2010, 184:5263-5270.
45. Fujisawa H., Shivji G., Kondo S., Wang B., Tomai M.A., Miller R.L., et al. Effect of a novel topical immunomodulator, S-28463, on keratinocyte cytokine gene expression and production. J Interferon Cytokine Res 1996, 16:555-559.
46. Inoue H., Nagata N., Koshihara Y. Involvement of substance P as a mediator in capsaicin-induced mouse ear oedema. Inflamm Res 1995, 44:470-474.
47. Atarashi K., Kabashima K., Akiyama K., Tokura Y. Skin application of the nonsteroidal anti-inflammatory drug ketoprofen downmodulates the antigen-presenting ability of langerhans cells in mice. Br J Dermatol 2008, 159:306-313.
48. Vissers W.H., van Vlijmen I., van Erp P.E., de Jong E.M., van de Kerkhof P.C. Topical treatment of mild to moderate plaque psoriasis with 0.3% tacrolimus gel and 0.5% tacrolimus cream: the effect on SUM score, epidermal proliferation, keratinization, T-cell subsets and HLA-DR expression. Br J Dermatol 2008, 158:705-712.